Pediatric Hematology, Onkology, and Hemostaseology -
Prof. Dr. Thomas Klingebiel

>

Expertise

• Treatment of pediatric leukemias and solid tumors according to the respective therapy study protocols; in vitro analysis of the interaction of cytostatic drugs with respect to new therapeutic options for high-risk patients
  
• Therapy of non-malignant pediatric hematologic diseases
  
• Allogeneic hematopoietic stem cell transplantation from HLA identical and non-identical donors
  
• High-dose chemotherapy with autologous stem cell rescue
  
• Development of cellular therapies: high-dose NK-cell therapy, gene modified T- and NK-cells, antigen specific T cells
  
• Fungal and gram negative infections during immunosuppression: genetic predisposition and treatment
  
  

>

Resources and Abilities

• Five color-flow cytometry
  
• MACS
  
• Real-time PCR, conventional PCR, RT-PCR, sequencing
  
• HPLC
  
• gene transduction
  
  

>

Staff

• Dr. Ulrike Köhl (cell therapy, molecular and cell biology, pharmacokinetics)
  
• Prof. Dr. Thomas Lehrnbecher (clinical studies, immunology, molecular biology)
  
• Prof. Dr. Dirk Schwabe (clinical studies)

>

Publications

• von Stackelberg A, Hartmann R, Buhrer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G. High-dose as compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood (2008) 111: 2573-2580.
  
• Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, Lochbuehler H, Kirsch S, Hallmen E, Veit-Friedrich I, Bielack SS, Niggli F, Kazanowska N, Ladenstein R, Wiebe T, T.Klingebiel T, Treuner J, Koscielniak E. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol (2008) 26: 406-13.
  
• Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, Dantonello T, Treuner J, Gadner H, Marky I, Kazanowska B, Koscielniak E. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial. Pediatr Blood Cancer (2008) 50: 739-745.
  
• Matthes-Martin S, Pötschger U, Bergmann K, Frommlet F, Brannath W, Bauer P, Klingebiel T. Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2008) 14: 335-43.
  
• Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, Chanock SJ. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol (2008) 9: 269-728.